2009-36: Optimization of the (cost)-effectiveness in the anti-VEGF-A therapy for exudative age-related macular degeneration.
The optimal frequency of Avastin injections for the treatment of ARMD is being investigated in study 2007-06. In addition to the medical outcome parameters, extensive quality of life measurements by means of a disease specific quality of life questionnaire (VFQ-25) and a generic quality of life questionnaire (SF-36) are part of the study outcome. The EQ-5D questionnaire, which will serve as a basis for analysis of cost effectiveness (cost per Quality Adjusted Life Years, QALYs) is added to the study as well. The research questions of this sub-study are: What is the optimal frequency of injections of Avastin in terms of quality of life and cost effectiveness (cost per QALY). Because we have chosen the same trial design as the pivotal trials of Lucentis, we are able to make an indirect comparison of the cost of Lucentis versus Avastin treatment for ARMD.